Eterna Therapeutics' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101
Eterna said the proof-of-concept study demonstrated "massive" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.
By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 "may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future," the company said.
Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.
Price: 0.4959, Change: +0.19, Percent Change: +60.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.